Navigation Links
Media Statement: Robert Moussa, President and CEO, Dilon Diagnostics
Date:8/26/2010

NEWPORT NEWS, Va., Aug. 26 /PRNewswire/ -- Radiation in any form brings risk. Medical radiation as a screening, diagnostic or treatment tool is designed with safeguards in mind to minimize the risk and maximize the benefit of the test or treatment. For instance, if a patient presents with a breast lump that can be felt but not viewed with mammography or ultrasound, medical professionals must employ the most appropriate diagnostic tools that identify potential cancer. By not doing so, the risk of missing cancers can be deadly.

Breast-Specific Gamma Imaging (BSGI) is a molecular breast-imaging exam that reveals metabolic activity, which is useful in the diagnostic work-up of a patient with suspected breast cancer. BSGI works on a cellular level that, with the aid of a radiopharmaceutical, identifies areas of increased activity that may indicate disease. BSGI is a complementary tool to mammography (an anatomical exam). In essence, mammography shows what the breast looks like and BSGI shows activity of the breast tissue.

A recent article in the journal Radiology by R. Edward Hendrick, Ph.D., makes a dubious comparison regarding the dose of radiation screening mammography (X-ray) to the radiation used in advanced diagnostic tools, such as BSGI and positron emission mammography (PEM). Dr. James Johnston, Professor of Radiologic Science at Midwestern State University in Texas notes that while this article provides important facts and useful information, the primary message should be one of appropriate use and not condemning any one modality based on an apples and oranges comparison.

As stated in the article, "a single BSGI or PEM is comparable in terms of dose and lifetime risk of cancer induction to a single chest, abdominal, or pelvic CT examination," which are ordered thousands of times each day in the U.S. Furthermore, the same radiopharmaceuticals used in BSGI and PEM studies are used in many other nuclear medicine exams every day such as cardiac stress tests and bone scans, in similar or higher radiation doses. And as Dr. Hendrick noted in the Radiology article, in most cases the balance of risk to benefit favors the use of imaging, but it is up to the patient in consultation with the physician to make an informed decision.

BSGI has led to the detection of countless breast cancers in patients across the U.S. and around the world. Many of these cancers were missed by mammography and ultrasound. BSGI is a recognized medical procedure that utilizes a radiopharmaceutical approved by the FDA, with guidelines for use by the Society of Nuclear Medicine, specifically, "Procedure Guidelines for Breast Scintigraphy with Breast-Specific Gamma Cameras."

Dilon Diagnostics is a medical manufacturer of the Dilon 6800®, a gamma camera optimized to perform BSGI, and is proud to be a leader in delivering such innovative life-saving technologies. "Our mission is to provide progressive healthcare products that enhance the capabilities of the attending physicians and the lives of the patients we serve," said Robert Moussa, President and CEO of Dilon Diagnostics. "We take this responsibility very seriously and would not promote the use of a product or procedure that we would not avail ourselves of." He adds that sensationalism by the media about medical radiation that alarms patients to the degree that they may opt out of potentially life-saving procedures is counterproductive.

About Dilon Diagnostics

Dilon Diagnostics, a brand of Dilon Technologies Inc., is bringing innovative medical imaging products to market. Dilon's cornerstone product, the Dilon 6800, is a digital high-resolution, compact gamma camera optimized to perform BSGI, a molecular breast imaging procedure which images the metabolic activity of breast lesions through radiotracer uptake. Many leading medical centers around the country are now offering BSGI to their patients, including: Cornell University Medical Center, New York; George Washington University Medical Center, Washington, D.C.; and The Rose, Houston. For more information on Dilon Diagnostics please visit www.dilon.com.


'/>"/>
SOURCE Dilon Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
2. Hospital to Hold MRSA Briefing for Media and Community Leaders
3. Superbug Outbreak Calls for Immediate Increased Attention on Infection Control
4. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
5. The OrthoGlide(TM) Medial Knee Implant Continues to be Accepted as an Alternative to Total Knee Replacement
6. Clinical Data Presented on OrthoGlide(R) Medial Knee Implant
7. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
8. Media Statement: MHA Keystone Center for Patient Safety & Quality OHRP Ruling
9. Cardium and Tissue Repair Companys Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
10. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
11. New Data From Phase 3 Study Suggests Tapentadol Immediate Release Effective for Acute Pain From Common Foot Surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... WILMINGTON, Del. , Sept. 6, 2017 NeuroRx, ... for Acute Suicidal Ideation and Behavior (ASIB), has been granted ... for its sequential therapy of NRX-100 (ketamine HCl) followed by ... patients in a pivotal trial of this sequential therapy targeting ... bipolar depression. 1 ...
(Date:9/5/2017)... Pa. , Sept. 5, 2017  Xyntek Inc. has announced another milestone ... a new Midwest office to meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 ... ... of customer engagements regionally. ...
(Date:9/5/2017)... Sept. 5, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral ... concluded its meeting with the U.S. Food and Drug ... formulation. At the ... pathway for submission of ORMD-0801, would be a Biologics ...
Breaking Medicine Technology:
(Date:9/21/2017)... ... September 21, 2017 , ... Preora Diagnostics Inc. ... screening tests, has received two prestigious recognitions that acknowledge the promise of its ... Preora has been named a Top 100 Finalist for the 16th annual ...
(Date:9/21/2017)... ... September 21, 2017 , ... FlipBelt, the fitness brand ... to detail to the athletic wear market with the launch of their FlipBelt Crops. ... have their essentials securely at their fingertips while at the gym, on the trail, ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... Month, Lewis and Clark College Emeritus Professor of Education Gregory A. Smith examines ... of Asleep at the Switch: Schoolhouse Commercialism, Privacy, and the Failure of ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... Coating System for clients that rely on safety and cleanliness. This unique flooring ... , Silver has been used for centuries for its antimicrobial properties. Unlike antibiotics, ...
(Date:9/20/2017)... ... ... Doctors on Liens has added the medical group Bones and Spine Surgery, ... personal injury lien basis. Founded by Dr. Wayne Cheng, MD and Dr. Gordon Yee, ... orthopedic injuries to patients in the Inland Empire. , Bones and Spines Surgery Inc ...
Breaking Medicine News(10 mins):